The LDN 2019 Conference

Watch and learn from LDN experts.

The LDN 2021 Conference Recordings Now Available with up to 29 CME Credits [More Details]

Medical Professionals Become an LDN Specialist [More Details]

The 2019 LDN AIIC Conference had discussions on the following disorders: ALS, Alzheimer's, anxiety, arthritis, autism, autoimmune hepatitis, brain fog, cancer, CFS, complex regional pain syndrome (CPRS), Crohn's, depression, diabetes, dissociative disorder, Epstein Barr virus, fibromyalgia, glioma, Graves’ disease, Hashimoto's, infertility, irritable bowel, leaky brain, leukemia, Lupus, Lyme disease, lymphoma, mast cell activation syndrome (MCAS), melanoma, mental health, mesothelioma, migraines, monoclonal gammopathy of undetermined significance (MGUS), movement disorder, MS, multiple sclerosis, multisystem disorders, myelodysplastic syndromes, obesity, opioid withdrawal, pain, Parkinson's, pituitary dysfunction, premenstrual syndrome (pms), psoriasis, PTSD, recurrent vaginitis, restless leg syndrome (rls), rheumatoid, SMALL intestinal bacterial overgrowth (SIBO), Sjogren's, stress, thyroid, tired brain syndrome, trauma, traumatic brain injury, ulcerative colitis, vulvodynia.


Akbar Khan, MD - LDN vs. Chemotherapy: One “Unproven” Therapy Against Another?


Armin Schwarzbach PhD, MD - Infections in Cancer and Autoimmune Disorders presented by Markus Berger


Elizabetheth Livengood NMD - LDN and MDD: A Case Study - Treating Depression in Patients with Autoimmune Conditions


Brian Udell MD - Low Dose Naltrexone - Key Ingredient in the biomedical Treatment of Autism Spectrum Disorder


Carrie Jones, ND, MPH - LDN and Cellular Hypothyroidism: When TSH is Normal but Reverse T3 is Elevated


Carrie Jones, ND, MPH - LDN and Cellular Hypothyroidism: Why you can't convert T4 into T3


Cory Tichauer ND - Immune Dysfunction in Post-Treatment Lyme Disease: Using Naltrexone to Balance Chronic Inflammation


Dana Keaton ND - Patient selection and inflammation


Dana Keaton ND - The scope of patient selection for LDN


Dr Harpal Bains MBBS - The role LDN plays in the body's hormonal symphony: how a well-conducted orchestra enhances the efficacy of LDN.


Dr Harpal Bains MBBS - Bioidentical hormones+asthetic+lifestyle


Elissa Mullen ND - Sleep - PTSD HPA Axis Dysregulation - LDN & The Gut Brain Barrier


Galyn Forster, MS, LPC - Treating Psychiatric Disorders with LDN Case Studies:Trauma-stress disorder, dissociative disorder, anxiety, phobia, pain and hypervigilance


Ginevra Liptan MD - Turning down the volume on fibromyalgia pain


Kent Holtorf, M.D - Causes of Hashimoto's


Kent Holtorf, M.D - LDN should be considered a first-line therapy for CFS/FM


Linda Elsegood - LDN, MS, The LDN Research Trust and Me


Mark Cooper, PhD - LDN, Endosomes and the Nanophysilogy of Autoimmune Movement Disorders 


Michael Ruscio, DC - The Gut-Thyroid Connection, Profound but Under Appreciated


Nasha Winters, ND - Using LDN to Quell the Over-Reactive Autoimmune Conditions Triggered by Many of Today's Cancer Drugs


Nasha Winters, ND - Quelling the side effects of immune therapies with LDN


Olga Cortez, MD - LDN Use in Women's Health


Pamela Smith, MD - LDN and Multiple Sclerosis


Pamela Smith, MD - LDN Use in Cognitive Decline, Lyme Disease, and Hashimoto’s Thyroiditis


Paul Battle, PA-C - Autoimmune Hepatitis


Prof Angus Dalgleish, MD - The role of LDN in cancer managemen


Sarah Zielsdorf, MD, MS - Graves' Disease



Sarah Zielsdorf, MD, MS - Traumatic Brain Injury: Low Dose Naltrexone and Microglial Modification


Sarah Zielsdorf, MD, MS - “Just Try LDN”: 3 years of insight from over 1,000 patients use of Low Dose Naltrexone


Stephen Dickson BSC (hons) MRPharmS - Mechanism of Action of Low Dose Naltrexone (LDN)


Steve Ottersberg MS - LDN, pain and immunity


Ted Cole, DO - The Use of LDN and Amino Acids in Parkinson's Disease


Ted Cole, DO - The Use of LDN in Parkinson's Disease


Ulrich Lanius, PhD - Naltrexone Dosing in Traumatic Stress and Dissociative Symptoms


Yoon Hang "John" Kim, MD - Treating chronic pain with low dose naltrexone and ultralow dose naltrexone


Yoon Hang "John" Kim, MD - Getting the most of LDN treatment and Beyond LDN


Mona Morstein ND - Using Low Dose Naltrexone To Help SIBO Patients


Andrew David Shiller MD - Is LDN a magic bullet for Fibromyalgia and Chronic Illness?


Sajad Zalzala, MD - What Patients Need to Know About Telemedicine


Amy Lamb Pharm - A Pharmacist's Perspective on Comprehensive Immune Health Consultations and Applications of LDN


Jill Cottel, MD - Treatment of Chronic Pain in a Free Clinic Setting


Leonard Weinstock, MD - Mast cell activation syndrome and potential role for LDN


Debbie Rice ND - LDN and vulvodynia


Scott Zashin MD - Treatment of Sjogren's Syndrome with LDN


Igor Schwartzman ND - The Art of LDN Prescribing In Hashimoto’s thyroiditis


Tara Thompson, PharmD - Compounding 101: The Basics of Compounding with Naltrexone


Jill Brook MA - Intermittent Fasting


Lesli Bitel, MBA, RDN, LDN - Client Attraction Secrets: Become a Sought After Expert With a Full Practice of Ideal, Committed Clients (Regardless of Insurance)


Andy Stein, PharmD - LDN for Opthalmic use


Samyadev Datta, MD - Pharmacology of Naltrexone Low dose Naltrexone in Chronic Pain Management 


Michelle Moser, Pharm - Making a difference


Phil Boyle MD - Low Dose Naltrexone treatment for Premenstrual Syndrome - PMS


James Iversen - Safety and Quality in Low-Dose Naltrexone Compounding


Debbie Hamilton, MD - Latest Th17 Research


Amber Myers, PharmD - Ocular Uses for Naltrexone


Question and Answer Sessions

Friday Morning


Friday Afternoon


Saturday Morning


Saturday Afternoon




Intellectual Property Rights

The intellectual property rights (including without limitation copyright and database rights) to the content in this website are owned by or licensed to the LDN Research Trust unless otherwise indicated.

Website content may be downloaded for personal, non-commercial use only. In all other cases, content originally published on the website may only be reproduced, stored, published or otherwise distributed in any form, with the written prior permission of the LDN Research Trust.